Walleye Capital LLC Acquires Shares of 20,691 InflaRx (NASDAQ:IFRX)

Walleye Capital LLC acquired a new stake in InflaRx (NASDAQ:IFRX) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 20,691 shares of the company’s stock, valued at approximately $51,000.

Other hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in InflaRx in the 4th quarter valued at $1,576,000. Commonwealth Equity Services LLC boosted its position in InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after buying an additional 19,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after buying an additional 11,900 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Stock Down 1.5 %

NASDAQ:IFRX opened at $1.30 on Monday. The stock’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $1.82. The firm has a market capitalization of $87.27 million, a P/E ratio of -1.20 and a beta of 2.21. InflaRx has a 12-month low of $0.82 and a 12-month high of $2.82.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. As a group, equities research analysts expect that InflaRx will post -1.04 earnings per share for the current year.

Analyst Ratings Changes

IFRX has been the topic of several recent research reports. Guggenheim raised their price target on InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.